Introduction: ROS1 rearrangement-positive NSCLC can be treated effectively with an anaplastic lymphoma kinase/ ROS1/mesenchymal-epithelial transition factor inhibitor such as crizotinib; however, the rate of response remains variable. Although several ROS1 fusion partners have been identified, the efficacy of crizotinib in patients with different types of ROS1 fusion partners is poorly understood.
Introduction
ROS1 fusion has now become a target in the treatment of NSCLC. 1, 2 The overall prevalence of ROS1 fusions is reported to be 2% in NSCLC [2] [3] [4] and up to 3.3% in lung adenocarcinoma. 5, 6 ROS1 chromosomal rearrangements were originally described in glioblastomas, in which ROS1 (chromosome 6q22) is fused with the fused in glioblastoma gene (FIG) . [7] [8] [9] [10] The kinase domain is fully retained on the ROS1 fusion protein, and the junction point at the mRNA level always occurs at the 5 0 end of exons 32 to 36. 11 Preclinical studies have demonstrated that ROS1 rearrangement cell lines are sensitive to the ROS1 kinase inhibitor crizotinib. 12 In a phase I study (PROFILE 1001 study) on 50 patients with ROS1-positive NSCLC treated with crizotinib, marked antitumor activity was observed and the objective response rate (ORR) was 69.8%. 13 Similarly, a European retrospective study reported impressive clinical activity with crizotinib against ROS1-positive lung cancer. 14 On the basis of the results from the phase I expansion cohort, crizotinib was approved in the United States for the treatment of patients with metastatic NSCLC who were positive for ROS1 fusion gene. In the largest study conducted to date on patients with ROS1-positive NSCLC, the median progression-free survival (PFS) was 15.9 months in 127 East Asian patients treated with crizotinib. 15 In 2007, ROS1 rearrangements were described in the lung cell line HCC78 with the fusion partner solute carrier family 34 member 2 gene (SLC34A2) and, in one patient's tumor, with the fusion partner CD74 molecule gene (CD74). 1 Since then, multiple other fusion partners have been identified, including FIG, syndecan 4 gene (SDC4), tropomyosin 3 gene (TPM3), ezrin gene (EZR), and leucine-rich repeats and immunoglobulinlike domains 3 gene (LRIG3). 3, 5 To date, 14 different types of fusion partner genes have been reported to combine with a range of ROS1 exons in lung cancer. 16 Previous studies have demonstrated that the activity of EGFR tyrosine kinase inhibitors (TKIs) differs among various types of EGFR mutations [17] [18] [19] and that the efficacy of crizotinib may be affected by different variants of ALK receptor tyrosine kinase gene (ALK). 20 It has been reported there was no apparent correlation between the specific ROS1 rearrangement and the duration of crizotinib treatment in the PROFILE 1001 study. However, given the small number of patients, the relationship between ROS1 fusion and the response to crizotinib is difficult to assess. The relationship between ROS1 fusion partners and the therapeutic efficacy of crizotinib is still poorly understood. The aim of this study was to examine the therapeutic efficacy of crizotinib in patients with different ROS1 fusion partners.
Materials and Methods

Patients
Between April 2014 and December 2016 tumors from more than 2400 patients with NSCLC were tested for ROS1 as well as for EGFR, ALK, BRAF, MNNG HOS Transforming gene (MET), and KRAS mutations. ROS1 gene rearrangement status was assessed by the reversetranscriptase polymerase chain reaction (PCR) method.
A specialist in lung cancer pathology assessed specimens' histologic features by using the WHO criteria, and patients' tumors were described according to the new International Association for the Study of Lung Cancer Classification. Thyroid transcription factor-1 and other immunostains were used to validate the diagnosis of NSCLC and exclude other malignancies.
A total of 49 patients (2.0%) with ROS1-positive advanced NSCLC were identified and treated with crizotinib. Of these patients, 36 (73.5%) had archived tumor specimens available for evaluation of ROS1 variants by Sanger sequencing. Given that the most common ROS1 fusion partner variant in ROS1-positive NSCLC is CD74-ROS1, the patients were divided into CD74-ROS1 and non-CD74-ROS1 groups. Data on clinicopathological variables and treatment response in these patients were collected retrospectively. Overall survival (OS) was defined as the time between the start of first-line therapy until date of death or the last follow-up visit. PFS was calculated from the start of crizotinib therapy until the date of Response Evaluation Criteria in Solid Tumorsdefined progressive disease (PD). The last date of follow-up was October 1, 2017, and the median followup time was 31.9 months. The study was approved by the institutional review board of the Shanghai Chest Hospital.
Reverse Transcriptase Qualitative PCR to Determine ROS1 Rearrangements In brief, total RNA was extracted from three to four sections of 3-mm-thick formalin-fixed, paraffinembedded tissue by using the AmoyDx FFPE RNA Kit (Amoy Diagnostics, Xiamen, People's Republic of China) as per the manufacturer's instructions. RNA was then reverse-transcribed into complementary DNA. PCR was further conducted to screen for ROS1 gene fusions on an Agilent Mx3000P QPCR instrument (Agilent Technologies, Santa Clara, CA) with the ROS1 fusion gene detection kit (Amoy Diagnostics) following the kit protocol. Quantitative judgments were made according to the fusion fluorescence signal. Assay reactions achieving threshold cycle values of fewer than 30 cycles were considered positive. b-Actin was used as an internal reference to ensure the quality of the extracted RNA, and ROS1-rearranged DNA was used as a positive control.
Direct Sequencing
The ROS1-positive cases underwent direct sequencing. PCR 
Treatment and Response
The initial dose of crizotinib administered to the patients was 250 mg twice per day; it was continued until PD or the occurrence of unacceptable toxicity; in patients who experienced toxicity the dose was reduced or temporarily interrupted. Evaluations of objective tumor responses were made by radiographic assessments according to the Response Evaluation Criteria in Solid Tumors, version 1.1. 21 The ORR was calculated as the percentage of patients with a complete response or partial response (PR). The disease control rate was defined as the percentage of patients with a complete response, PR, or stable disease.
Statistical Analysis
Continuous variables were summarized as means and SDs or medians with range, and categorical variables were summarized as frequencies with percentage. An unpaired t test or Wilcoxon test was used for comparison of continuous variables and a chi-square or Fisher's exact test was used to compare categorical data, as appropriate. The Kaplan-Meier method was used to estimate survival rate, along with a log-rank test comparing the survival distribution. The Cox proportional hazards model was used for multivariable survival analysis. Variables with a p value less than 0.2 in the univariate analysis were included in the multivariate analysis. Schoenfeld residuals were used to check the proportional hazards assumption. All tests were two sided, and p values less than 0.05 were considered statistically significant. All statistical analyses were performed with R software (version 3.3.3, R Foundation for Statistical Computing, Vienna, Austria) and RStudio software (version 1.1.383).
Results
Patient Characteristics
The general demographic and clinical characteristics of the 36 patients included in the study are presented in Table 1 . The median age was 50.8 years (range 32-78 years) and most of the patients were female (n ¼ 23 [63.9%]) and nonsmokers (n ¼ 31 [86.1%]). The disease of 30 patients (83.3%) was diagnosed as stage IV disease, whereas six patients (16.7%) had postoperative recurrent disease. All patients had an Eastern Cooperative Oncology Group performance status of 0 to 2.
In 14 patients (38.9%) crizotinib was used as firstline treatment, in 15 patients (41.7%) it was used as second-line treatment, and in seven (19.4%) it was used as third-line or later treatment. On follow-up 30 patients (83.3%) achieved a PR with crizotinib treatment, whereas five patients (13.9%) had stable disease, and one (2.8%) had PD.
Identification of ROS1 Fusion Partners
On the basis of the ROS1 fusion partners identified ( Supplementary Fig. S1 and Supplementary Table 1), 19 patients were assigned to the CD74-ROS1 group and 17 to the non-CD74-ROS1 group. Figure 1 shows frequency of the ROS1 fusion partners identified. The most frequent ROS1 fusion pair was CD74-ROS1 (CD74-E6 and ROS1-E34), which was identified in 16 patients (44.4%). Dual CD74-ROS1 (CD74-E6 and ROS1-E32/34) was observed in two patients (5.6%), and CD74 plus SDC4 (SDC4-E2, ROS1-E32/CD74-E6, and ROS1-E34) was observed in one patient (2.8%). In the non-CD74-ROS1group, the ROS1 fusion pairs identified included EZR-ROS1 (EZR-E10 and ROS1-E34), which was found in seven patients (19.4%), and SDC4-ROS1 (SDC4-E2 and ROS1-E32), which was found in four patients (11.1%). SLC34A2-ROS1 (SLC34A2-E14del and ROS1-E32), TPM3-ROS1 (TPM3-E8 and ROS1-E35), and SDC4 plus EZR-ROS1 (SDC4-E2, ROS1-E32/EZR-E10, and ROS1-E34) were observed in two patients (5.6%) each.
Correlation between Clinical Outcomes and Different ROS1 Fusion Partners
The patients' clinical characteristics as stratified by variant fusion partners are shown in Table 2 . All clinical (Fig. 2A) . Figure 3A shows Table 3 ).
The median OS times in all patients, patients in the CD74-ROS1 group, and patients in the non-CD74-ROS1 groups were 32.70 (IQR ¼ 18.77-not reached), 24 Figure 3B shows the patients' OS according to the individual type of ROS1 fusion partners. In univariate analysis, the OS of patients in the non-CD74-ROS1 group was significantly (Fig. 2B) . All results of the univariable and multivariable survival analyses are listed in Table 4 . In multivariable Cox model analysis, brain metastasis before crizotinib treatment (HR ¼ 8.973, 95% CI: 1.723-46.720, p ¼ 0.010) was an independently significant prognostic factor for shorter OS. It should be noted that both CD74-ROS1 fusion and smoking were associated with shorter survival, although the associations were not statistically significant (see Table 4 ).
Brain Progression and Different ROS1 Fusion Partners
At the time of last follow-up, 23 patients (63.9%) treated with crizotinib had PD. Among these patients, brain progression was observed in six patients (26.1%), including three in the CD74-ROS1 group and three in the non-CD74-ROS1 group. Of these six patients, five had no brain metastases at baseline before crizotinib treatment. The rate of brain progression after crizotinib treatment was 21.4% in the CD74-ROS1 group (three of 14) and 33.3 % in the non-CD74-ROS1 group (three of nine), with no significant difference between the two groups (p ¼ 0.643). All six patients received whole brain radiotherapy. The intracranial disease of five patients was controlled. The PFS and OS for six patients whose disease progressed in the brain are presented in Figure 3A and B.
Discussion
Recently, studies have evaluated the role of multiple variants of tumor mutation in response to TKIs in patients with NSCLC. The activity of EGFR TKIs has been reported to differ among various types of EGFR mutations, which are the most common driver mutations in NSCLC. 17, 19 Studies of common EGFR mutations (deletion mutations in exon 19 [Del19] and the Leu858Arg point mutation in exon 21 [L858R]) have indicated that better responses to EGFR TKI therapy are associated with Del19 mutations than with L858R mutations. 22, 23 Therefore, the difference in prognosis between EGFR Del19 and L858R disease might be correlated with the efficacy of EGFR TKIs. In another study, 20 which reported that crizotinib is more effective in patients with ALK variant 1 than those who did not have ALK variant 1, the median PFS was significantly longer in the ALK variant 1 group than in the group without ALK variant 1. A retrospective study conducted in Korea also had similar findings, the variant-specific genotype of the echinoderm microtubule associated protein like 4 gene (EML4)-ALK fusion allowed for more precise stratification of these patients. 24 In this retrospective study, we have attempted to evaluate the effects of various ROS1 fusion partners in response to crizotinib, as for different EGFR mutations and ALK variants in NSCLC.
Our study had two important findings. First, the ORR was higher in the non-CD74-ROS1 group. These data suggest that ROS1 fusion partner may be an important factor that influences the efficacy and prognosis for patients with advanced ROS1-rearranged NSCLC. The ORR of crizotinib was 83.3% for all patients in our study, which is higher than that found by Shaw et al. (72%). 13 We found that the most common ROS1 fusion partner was the CD74 gene (44.4%), which is consistent with the findings of Shaw et al. (in 11 of 25 samples [44%]). 13 However, more patients received first-line therapy in our study (38.9%) than in the study by Shaw et al. (14%). We therefore speculate that this is the reason why we had a higher ORR than Shaw et al. did.
Second, a trend toward favorable OS and PFS among patients with non-CD74-ROS1 variants was observed as compared with the OS and PFS among patients with CD74-ROS1 variants when treated with crizotinib. Although this trend was not significant on the multivariate analysis, we believe that it should be explored further. The sample size is likely an important limitation contributing to the observation in the multivariate analysis. In the future, more patients will be required in order to confirm the finding that stratification of patients with advanced ROS1 rearrangement-positive NSCLC by the variant-fusion partners could help predict clinical efficacy.
In our study, brain metastases occurred in 16.7% of patients (six of 36), which is consistent with result The results for six patients with progression in the brain are presented. In the non-CD74-ROS1 group, the PFS times with crizotinib among the patients with progression in the brain (patients 11, 12, and 16) were 11.6, 10.3, and 4.4 months, respectively, and their OS times were 18.7, 44.5, 16.6 months, respectively. In the CD74-ROS1 group, the PFS times with crizotinib among the patients with progression in the brain (patients 2, 4, and 9) were 20.4, 18.3, and 12.8 months, respectively, and their OS times were 29.5, 24.3, and 15.2 months, respectively.
reported in the study by Gainor et al. (19.4%) 25 and that reported in the study of East Asian patients by Wu et al. (18.1%) 15 ; however, patients with ROS1-positive NSCLC seemed to have a lower prevalence of brain metastases than ALK-positive patients did. 25 Another clinically relevant finding was that all patients with brain metastases before crizotinib treatment had CD74-ROS1 fusion pairs. Multivariable analysis identified presence of brain metastasis before crizotinib treatment as a predictor of worse OS. This finding suggests that patients in the CD74-ROS1 fusion group may be more susceptible to brain metastases. However, we could not prove a causal relationship given the limited sample size. CD74-ROS1 fusion could potentially represent the underlying mechanism behind poorer survival in these patients. Although we found no significant difference in the central nervous system progression rate between the CD74-ROS1 and non-CD74-ROS1 groups after crizotinib treatment, larger numbers of patients with CD74 fusion partners had brain metastases before initiation of crizotinib.
Previous studies have examined the transforming potential of cancer-related ROS1 fusion proteins. Expression of known fusion variants in fibroblasts has been shown to result in anchorage-independent growth, foci formation, and tumorigenicity. The ROS1 transmembrane domain is often lost in rearrangements, and as a consequence, the fusion protein is relocalized from the plasma membrane to the cytoplasm. 1, 5, 26, 27 This relocation can lead to interactions with different substrates and/or differential commitments in signaling pathways that are important for cell transformation. 4, 10, 26 Several studies have examined the signaling pathways that are activated by ROS1 fusion proteins. Expression of FIG-ROS1 , CD74-ROS1, and SDC4-ROS1 fusions in fibroblasts or Ba/F3 cells has been shown to result in autophosphorylation of ROS1 and phosphorylation of SH2 domain-containing tyrosine phosphatase 2, MAP-ERK kinase, ERK, signal transducer and activator of transcription 3, and AKT, and these effects were blocked by pharmacological inhibition of ROS1. 4, 10, 26, 28 , ROS1 inhibitors also led to reductions in phosphorylated ROS1, SH2 domaincontaining tyrosine phosphatase 2, AKT, and ERK in HCC78 cells. 4, 12 One report has suggested that downstream signaling may differ depending on the fusion partner of ROS1, as it was observed that CD74-ROS1 but not FIG-ROS1 led to phosphorylation of E-Syt1 and that this differential signaling activity led to a more invasive phenotype of CD74-ROS1-transduced cells. 28 These findings support those obtained in the present study and may explain why patients in the non-CD74-ROS1 group had better survival and were less likely to have brain metastases. Recently, a study by Lin et al. 29 indicated that different ALK variants will drive different resistance mutations. In our study, we identified five patients who underwent biopsies after disease progression. Four specimens were analyzed for ROS1 resistance mutations by using next-generation sequencing and one was analyzed by Sanger sequencing. ROS1 G2032R resistance mutations were identified in specimens from two of five patients (40%). These two patients were in the CD74-ROS1 group. In the study by Gainor et al., 25 ROS1 mutations included G2032R (41%), D2033N (6%), and S1986F (6%). More samples will be needed to evaluate the frequency and spectrum of ROS1 fusion variants with acquired TKI resistance and the clinical outcomes of patients with these variants who received crizotinib.
Concurrent occurrence of dual ROS1 fusions has been described. Cai et al. 30 determined that SLC34A2-ROS1 (S13del; R32) and SLC34A2-ROS1 (S13del; R34) coexisted in a female never-smoker with adenocarcinoma, and they also reported coexistence of three variants involving two different fusion partners of ROS1 in lung adenocarcinoma. 31 Five dual ROS1 fusions were also found in our study. This finding of dual ROS1 fusions may be explained by heterogeneity in the tumor tissue.
This study had several limitations. First, it was a retrospective study with a relatively short follow-up period, and the intervals between imaging studies were not consistent. This limitation can be addressed by designing a prospective multicenter study. Second, it was a single-institution study with a limited sample size. A heterogeneous group of fusion partners was compared with a semipure group because of the rarity of these patients. Future studies evaluating a larger sample size would be important to further validate these findings.
In conclusion, this is the largest study to date to evaluate the roles of ROS1 fusion partners in treatment response. We found that patients with non-CD74-ROS1-positive NSCLC are less likely to have brain metastases. Furthermore, although not significant, a trend toward improved survival was observed in patients in the non-CD74-ROS1 group. These findings could help direct targeted therapy on the basis of their ROS1 fusion partners in patients with ROS1-positive NSCLC. Large multicenter, prospective studies are required to confirm the specific associations between ROS1 fusion partners and the efficacy of crizotinib.
